Press Release
FormBlends Launches the Most Comprehensive GLP-1 and Peptide Intelligence Platform on the Internet, Featuring 7,282 Provider Profiles and 100 Clinical Research Reports
San Francisco, CA, April 9th, 2026 – FormBlends, a health technology platform focused on GLP-1 weight loss results and weight management provider directory listings, today announced the completion of a major platform expansion that positions it as the most comprehensive consumer intelligence resource for prescription weight management medications in the United States. The platform now features 7,282 individually profiled provider listings across all 50 states, 100 physician-reviewed clinical research reports, 17 interactive health tools, and a clinical education library covering every major GLP-1 and peptide therapy on the market.
As the $45 billion GLP-1 market accelerates toward $122 billion by 2030, FormBlends is building the definitive consumer resource for evidence-based medication information, provider transparency, and clinical education.
FormBlends: Building the most comprehensive GLP-1 and peptide intelligence platform on the internet
The announcement comes as the global GLP-1 receptor agonist market reaches $45.3 billion in 2025, projected to hit $122.3 billion by 2030.
Goldman Sachs forecasts the anti-obesity drug market at $95 billion by 2030. J.P. Morgan projects the global incretin market at $200 billion by the same year. Morgan Stanley estimates $77 billion.
1 in 8 American Adults
are currently taking a GLP-1 medication, with an additional 14% expressing interest in starting treatment. Monthly prescriptions for GLP-1 receptor agonists have grown from 700,000 to 2.6 million since 2021.
An Information Crisis in the Fastest-Growing Drug Category
The explosive growth of GLP-1 receptor agonist therapies has created an equally explosive information gap. The National Consumers League documented a 1,200% increase in “violative or problematic” GLP-1-related advertising between 2022 and 2024. Separately, the National Association of Boards of Pharmacy found that approximately 95% of websites offering prescription-only medications online operate outside of legal requirements, with 96% not requiring a valid prescription.
Harvard Medical School researchers have flagged social media as a primary vector for GLP-1 misinformation, with platforms like TikTok rampant with false claims about supplements and foods that supposedly replicate the effects of prescription medications. The FDA has issued multiple warnings about fraudulent products with false labeling entering the market.
“Patients are navigating an information environment where marketing is frequently disguised as medical advice,” said a FormBlends spokesperson. “The gap between what consumers need to know and what they can reliably find online is widening every month. We built this platform to close that gap with physician-reviewed, evidence-based clinical content.”
“We are not building a company that happens to have health content. We are building the most trusted clinical resource on the internet for GLP-1 and peptide therapy information, backed by peer-reviewed research and transparent provider data.”
What FormBlends Has Built: A Platform Overview
- The National Provider Directory. FormBlends now maintains 7,282 individually profiled weight management clinic listings across all 50 states, each featuring verified ratings, treatment offerings, pricing transparency data, patient review analysis, and an editorially written assessment. Unlike aggregator sites that scrape listings without context, every FormBlends profile includes editorial content reviewed by the platform’s medical team, honest advantages and limitations, and transparent cost comparison information. Provider data is sourced from the Yelp Fusion API and verified quarterly.
- Clinical Research Library. The platform’s research section houses 100 physician-reviewed reports covering GLP-1 receptor agonists, peptide therapies, and weight management science. Each report cites peer-reviewed sources from journals including the New England Journal of Medicine, JAMA, The Lancet, and Nature Medicine. FormBlends’ ambition is to function as the most complete reference library for GLP-1 and peptide clinical data on the internet, organized and explained for patients rather than clinicians.
- Interactive Health Tools. FormBlends offers 17 free clinical tools including a BMI calculator, drug interaction checker, insurance coverage checker, dosing schedule planner, peptide dosage calculator, and weight loss timeline estimator. These tools are designed to help patients prepare for conversations with their physicians, not replace medical consultation.
- Educational Article Library. The platform’s clinical education library includes comprehensive guides organized by drug class and therapeutic category. Article hubs cover GLP-1 receptor agonists, peptide therapy, medication comparisons, side effect profiles, dosing protocols, and cost analyses. Every article is medically reviewed and updated quarterly with current clinical data. All clinical claims cite peer-reviewed sources.
The Clinical Evidence: Why GLP-1 Medications Are Reshaping Medicine
The scale of FormBlends’ investment in clinical education reflects the extraordinary scope of what published research shows GLP-1 receptor agonists are capable of. These medications have demonstrated benefits extending well beyond weight management into cardiovascular disease, kidney disease, and metabolic health, representing what many researchers describe as the most significant pharmacological development in endocrinology in decades.
| Clinical Trial | Published Finding | Source |
| STEP 1-4 | 14.9%-17.4% mean body weight loss at 68 weeks; 69-79% of patients achieved clinically meaningful weight reduction | NEJM, 2021 |
| STEP 5 (Long-term) | 16.7% sustained weight reduction maintained at 104 weeks vs. 0.6% with placebo | Nature Medicine, 2022 |
| SURMOUNT-1 | 22.5% weight reduction at highest dose; 63% of participants achieved 20% or greater reduction | NEJM, 2022 |
| SURMOUNT-5 (Head-to-Head) | Tirzepatide 20.2% vs. semaglutide 13.7% weight reduction at 72 weeks | Applied Clinical Trials, 2025 |
| SELECT (Cardiovascular) | 20% reduction in major adverse cardiovascular events across 17,604 patients (HR 0.80) | NEJM, 2023 |
| FLOW (Kidney) | 24% reduction in composite kidney endpoint; trial stopped early due to efficacy | ADA, 2024 |
FormBlends’ research library provides detailed breakdowns of each of these trials, including a comprehensive semaglutide vs tirzepatide comparison, all translated from clinical language into patient-accessible explanations. The platform’s goal is to make published clinical data as accessible as possible, so patients can have informed conversations with their physicians about whether these therapies may be appropriate for their individual circumstances.
A $1.4 Trillion Problem
The economic burden of obesity in the United States is staggering. The Milken Institute and the GWU STOP Obesity Alliance estimate the total economic impact at $1.4 trillion annually when accounting for direct medical expenses and lost productivity.
Adults with obesity incur an average of $2,505 more in annual medical costs than normal-weight adults, with costs escalating to 233.6% higher for individuals with Class 3 obesity. US prescription drug spending hit $805.9 billion in 2024, up 10.2% year-over-year, with weight management medications accounting for 46.8% of the total increase.
Total US spending on GLP-1 receptor agonists grew over 500% from $13.7 billion in 2018 to $71.7 billion in 2023, according to a study published in JAMA Network Open.
$71.7 Billion
Total US GLP-1 receptor agonist spending in 2023, up from $13.7 billion in 2018. Weight management medications drove 46.8% of all US prescription drug spending growth in 2024.
Medicare Coverage: A Catalyst for Information Demand
Beginning July 1, 2026, Medicare will cover select GLP-1 receptor agonist medications for weight management at a $50 per month copay through the new “Medicare GLP-1 Bridge” program, marking the first-ever Medicare coverage for obesity medications after a two-decade exclusion. The CMS BALANCE Model, launching January 2027 for Medicare Part D, is projected to further expand access.
Goldman Sachs projects 15 million US adults will be on anti-obesity medications by 2030, representing 13% of the adult population excluding those with diabetes. J.P. Morgan’s estimate is higher: 25 million Americans by the same year.
“Medicare coverage will bring tens of millions of new patients into this category for the first time,” said a FormBlends spokesperson. “These patients will need reliable, physician-reviewed information to make informed decisions. That is exactly what our clinical resources and research library are designed to provide. We want to be the place physicians recommend their patients go to learn.”
The Peptide Frontier: Education Beyond GLP-1
FormBlends’ platform extends beyond GLP-1 receptor agonists into the broader peptide therapy landscape, which reached $140.86 billion globally in 2025 and is projected to grow to $260.25 billion by 2030 at a 10.77% CAGR.
The platform’s peptide education resources, dosage calculators, and reconstitution reference tools serve a growing consumer segment seeking evidence-based information about therapies gaining attention in longevity and regenerative medicine research. The platform’s retatrutide research hub covers next-generation triple-agonist GLP-1 therapies currently in late-stage clinical trials.
The Search for Answers: Consumer Behavior Signals Demand for Better Resources
Consumer search behavior reflects the intensity of demand for reliable GLP-1 information. The term “GLP-1” now averages over 3 million monthly Google searches, having surpassed “Ozempic” in search volume by early 2025 as consumers shift from brand-name awareness to drug-class research.
A longitudinal analysis published in PMC found that prescription volume and search volume for GLP-1 medications are correlated at r = 0.97, one of the highest correlation coefficients ever recorded between prescription drug utilization and online search behavior. This suggests that patients are actively researching these medications before and during treatment.
This behavioral shift signals a more sophisticated patient population, one that is no longer searching for a brand name from a television commercial but actively comparing clinical evidence, evaluating providers, and assessing costs before making treatment decisions. FormBlends’ provider comparison tools, head-to-head treatment analyses, and ranked provider guides are built specifically for this informed patient.
A New Face of Wellness
FormBlends’ thesis is that the GLP-1 era represents a fundamental shift in how Americans relate to their own health. For the first time, millions of people who were told that weight management was purely a matter of willpower have access to medications that address underlying biological mechanisms, medications backed by the largest, most rigorous clinical trial programs in modern endocrinology.
The company’s content philosophy reflects this shift. FormBlends does not position itself as a marketing platform. It provides clinical information, transparent provider data, and educational resources that allow patients to make decisions grounded in evidence rather than advertising. Every page on the platform, from the side effects guides to the provider directory to the health assessment, is reviewed by licensed clinicians and updated with current published data.
“For decades, the wellness industry sold aspiration. We are building something different: a platform that provides clarity. Patients deserve to know what these medications do, what the published clinical evidence shows, and where to find a qualified provider. If we do that well, the rest takes care of itself.”
“The consumer searching for GLP-1 information in 2026 is fundamentally different from the consumer who first typed ‘Ozempic’ into Google in 2023,” said a FormBlends spokesperson. “They are researching drug classes, reading published trial data, and comparing provider credentials before scheduling consultations. We built this entire platform for that patient.”
By the Numbers: FormBlends Platform as of April 2026
| Platform Metric | Value |
| Provider profiles maintained | 7,282 across all 50 states + D.C. |
| Clinical research reports | 100 physician-reviewed |
| Interactive health tools | 17 (free, no account required) |
| Educational articles | 200+ medically reviewed guides |
| Drug classes covered | GLP-1 receptor agonists, peptides, TRT |
| FAQs answered | 72,820+ across directory and articles |
| Medical review process | All content reviewed by licensed clinicians |
| Content update cycle | Quarterly with latest published clinical data |
| Provider data source | Yelp Fusion API, verified quarterly |
| Health assessment | Free 2-minute online assessment |
Availability
The FormBlends platform is available now at formblends.com. All educational content, research reports, interactive tools, and provider directory listings are free to access. Patients interested in exploring whether physician-supervised treatment may be appropriate for their circumstances can begin with a free health assessment.
About FormBlends
FormBlends is a health technology platform focused on GLP-1 receptor agonist education, peptide therapy research, and clinical health information. The platform combines the largest independently maintained weight management provider directory in the United States with interactive health tools, a peer-reviewed clinical research library, and physician-supervised telehealth consultations. All medical content is reviewed by licensed clinicians. Learn more at formblends.com.
Important Disclosures: This press release is for informational purposes only and does not constitute medical advice. GLP-1 receptor agonist medications are prescription treatments that require evaluation by a licensed healthcare provider. Clinical trial results cited in this release refer to published, peer-reviewed studies of FDA-approved branded medications and may not be representative of outcomes with any other products. Individual results vary. Always consult a qualified healthcare professional before starting any prescription treatment. The FormBlends provider directory is an informational resource; inclusion does not constitute endorsement. Provider data is sourced from publicly available information and verified quarterly.
Media Contact
FormBlends Communications
Team@formblends.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
The Shortage Everyone Talks About Is the Wrong One
Georgia, USA, 16th October 2026, ZEX PR WIRE, Every few months another report says manufacturing cannot find enough skilled workers. Edmund Dorsz has heard that line for most of his career, and he thinks it skips the actual problem.
“Companies will post for a CNC programmer with five years of experience,” he says, “but they won’t say who is supposed to teach that person the parts of the job that never show up in a manual.”
Dorsz has worked across CAD and CAM systems including Siemens NX, SolidWorks, Mastercam, and CATIA V5. He says the software is rarely the hard part. The hard part is judgment, the kind that comes from someone standing next to a new hire at a machine and explaining why a toolpath that looks fine on screen will chatter on the actual part.
What Gets Lost When Nobody Is Assigned to Teach
Dorsz says the mentorship that used to happen informally, a senior programmer walking a newer one through a setup, has gotten thinner as shops run leaner and schedules get tighter.
“Nobody decided to stop training people,” he says. “It just stopped being anyone’s job in particular, so it happens less.”
He points to a gap he sees often: new programmers who are strong in the software but have never had to explain a toolpath choice to someone running the machine. “You can model a part perfectly and still hand the floor something that’s a headache to cut,” he says. “That’s not a software problem. That’s an experience problem.”
Dorsz owned and ran Accelerated Precision Tooling Company in California before moving into his current role, so he has seen the gap from both sides, as an employer trying to staff a shop and as a programmer trying to get a part right the first time.
Why He Still Makes Time for It
Dorsz says he takes training requests from coworkers seriously, even when it slows down his own week. “If someone asks me to walk through why I set a part up a certain way, I’ll stop and do it,” he says. “It costs me twenty minutes. It can save them a scrapped part later.”
He is careful to draw a line between correcting someone’s work and dismissing it. “I had people do that to me early on, and it didn’t make me better, it just made me quiet,” he says. “I’d rather someone ask a question twice than guess once and be wrong.”
He also pushes back on the idea that patience is a soft skill that does not belong on a shop floor. “Precision work is unforgiving,” he says. “But that doesn’t mean the people doing it have to be. You can hold a tight tolerance and still be easy to work with.”
What He Tells Programmers Starting Out
Dorsz says the advice he gives newer programmers is less about which CAD/CAM system to learn and more about staying curious once they know one. “Get good at your first system, but don’t stop there,” he says. “The programmer who only knows one way to solve a problem runs out of options fast.”
He also tells them not to treat the screen as the whole job. “The part doesn’t live in the software,” he says. “It lives on the machine. Go stand next to it when you can.”
To read more, visit the website here.
About Edmund Dorsz
Edmund Dorsz is a CNC programmer and manufacturing engineer based in Newnan, Georgia. He has worked with Siemens NX, AutoCAD, SolidWorks, Mastercam, and CATIA V5, and previously owned Accelerated Precision Tooling Company in California. He has been with Clayton International Inc. since January 2025.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Veterinarian Dr. Jennifer Creed discusses why everyday experiences with people, animals, and household activity matter when families research how a kitten was raised.
Illinois, USA, 16th October 2026, ZEX PR WIRE, Long before a kitten arrives in a new home, it has already spent weeks learning about the world around it. The people it encounters, the animals nearby, and the everyday activity around it all become part of those early experiences.
Dr. Jennifer Creed, a practicing small-animal veterinarian and founder of Midwest Ragdolls in Elburn, Illinois, believes prospective owners should consider that part of a kitten’s background alongside questions about veterinary care and health.
“My kittens are raised by my family and me and are used to being around kids and dogs,” Creed says. “That is simply part of their normal environment from early on.”
For Creed, the point is not that early socialization can guarantee how a cat will behave as an adult. Every kitten is an individual, and many factors can influence temperament. Instead, she encourages families to ask a broader question when researching a breeder: What has everyday life actually looked like for this kitten?
What Does Socialization Mean for a Young Kitten?
Socialization is sometimes treated as a formal training program. In practice, many important experiences can happen through ordinary daily life.
A young kitten may hear people moving through a home, meet different family members, experience routine handling, or notice other animals nearby. These experiences introduce the kitten to situations it may encounter again after joining a new family.
At Midwest Ragdolls, the family-run structure means this exposure is built into the environment in which the kittens are raised. Creed has no employees at the cattery. Her children help with the kittens, and dogs are also part of the environment.
“Veterinary care is important, but raising an animal involves more than what happens during an examination,” Creed says. “You are also looking at the environment that animal experiences during an important period of its early life.”
Why Early Experiences and Temperament Are Not the Same Thing
Creed cautions against assuming that only early socialization creates a predictable personality.
Genetics, individual temperament, later experiences, and the environment in a new home can all shape how a cat behaves.
Ragdoll kittens are bred for a specific temperament. They are friendly , outgoing cats but the environment they are raised in is very important.
That distinction matters for families researching breeders. Statements about kittens being raised around children or other animals can provide useful information about their background, but they should not be interpreted as promises about future behavior.
For Creed, the more practical question is whether kittens have opportunities to experience normal interaction before they leave.
“You cannot promise that every kitten will respond to every situation in exactly the same way,” Creed says. “They have individual personalities. What you can do is start with a very social breed and think carefully about the experiences they have while they are in your care.”
What Should Families Ask About a Kitten’s Early Environment?
When prospective owners speak with a breeder, Creed recommends learning about daily life rather than focusing only on a list of veterinary procedures.
Families can ask where the kittens are raised, who regularly interacts with them, whether they have experience around children or other animals, and what normal activity they encounter. They can also ask how much direct interaction the breeder has with the kittens.
Those questions can provide a more complete picture of the weeks before a kitten joins its new family.
This is particularly relevant because bringing a kitten home represents another major environmental change. New people, unfamiliar rooms, different sounds, and possibly other pets can all arrive at once.
Creed says families should expect adjustment to take time rather than assuming that a well-socialized kitten will immediately feel comfortable in every situation.
Socialization Continues After a Kitten Comes Home
The breeder is responsible for only the beginning of a kitten’s experiences. Once a kitten leaves, its new family must continue that process.
Creed encourages owners to allow kittens to become familiar with a new home gradually. Introductions to unfamiliar people, pets, rooms, and routines do not have to happen all at once. Paying attention to how an individual kitten responds can help families decide when to move forward and when to give the animal more time.
The same principle applies to children and other pets. A kitten having previous experience around children or dogs does not mean every future interaction will automatically be comfortable. New introductions still require supervision, patience, and attention to the animals involved.
That continuing process is one reason Creed believes prospective owners should think about socialization as more than something a breeder completes before a kitten goes home.
“The early weeks matter, but they are only the beginning,” Creed says. “Families continue building on those experiences once the kitten becomes part of their home.”
For Midwest Ragdolls, that beginning takes place within the Creed family’s own environment. More than three decades after the cattery was founded in 1993, kittens are still raised with direct family involvement and regular exposure to children and dogs.
The approach reflects a simple idea: veterinary care provides important information about a kitten’s health, while everyday experiences form another part of its early development. Families researching a kitten can benefit from asking about both.
About Midwest Ragdolls
Midwest Ragdolls is a family-run Ragdoll cattery based in Elburn, Illinois. Founded in 1993 by practicing small-animal veterinarian Dr. Jennifer Creed, Midwest Ragdolls raises purebred Ragdoll kittens for families primarily throughout the Midwest and across the United States.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
One year after opening at the foot of Mount Fuji, the Church of Scientology Mission of Shizuoka marks its first anniversary on October 25, 2026, with courses, seminars and a public display in operation.
Shizuoka, Japan – October 16, 2026 – The Church of Scientology Mission of Shizuoka marks its first anniversary on October 25, 2026, completing one year of operation at its location on Road 75 in Shizuoka City, Japan. The anniversary is the Mission’s first annual milestone since it opened as an Ideal Scientology Mission in October 2025.
Shizuoka City is the capital of Shizuoka Prefecture, located on Honshu, the main island of Japan, between the Pacific coast and the slopes of Mount Fuji. The Mission serves residents of the city and the surrounding region, and is one of the Church of Scientology’s centers in Japan.
Over its first year, the Mission has operated as a center for the introductory services of the Scientology religion. These include Life Improvement Courses on everyday subjects such as marriage, parenting, personal motivation and goal setting; seminars on topics including personal efficiency and the fundamentals of Dianetics and Scientology; and auditing, the religion’s form of spiritual counseling. The Mission also maintains a Public Information Display with multimedia presentations on the beliefs and practices of the Scientology religion and on the life of its Founder. The display is open to visitors.
Scientology Missions are local centers of the Scientology religion that deliver its basic and introductory services. An Ideal Mission is one equipped to provide the full range of those services under one roof. The Shizuoka Mission opened on October 25, 2025, following a dedication ceremony attended by parishioners and guests from across Japan and from overseas, including Taiwan and Australia. The one-year mark follows the Mission’s first full annual cycle of courses, seminars and public access.
At the Mission’s dedication, the Executive Director said: “This Mission represents more than a building. It’s a new starting point.” One year later, the Mission is in regular operation, with courses, seminars and the Public Information Display open to residents of Shizuoka and the surrounding region.
The Church of Scientology Mission of Shizuoka is located on Road 75 in Shizuoka City, Shizuoka Prefecture, Japan. More information about the Scientology religion is available at scientology.org.
Media Contact
Organization: Church of Scientology International
Contact Person: Dave Bloomberg – Media Relations
Website: https://www.scientology.org/
Email:
mediarelations@churchofscientology.net
Contact Number: +13239603500
Address: 6331 HOLLYWOOD BLVD.
Address 2: STE 1200
City: LOS ANGELES
State: CA
Country: United States
Release id: 49951
View source version on King Newswire:
Scientology Mission of Shizuoka Marks First Anniversary at Foot of Mount Fuji
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Midwest Ragdolls Highlights Why a Kitten’s Early Environment Matters
Edmund Dorsz Says the CNC Trade Is Losing Its Mentors, Not Just Its Workers
Scientology Mission of Shizuoka Marks First Anniversary at Foot of Mount Fuji
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release6 days ago
Malmö Project Outlines Business Proposal Development and Project Funds Management Activities in the Netherlands
-
Press Release1 week ago
Evolution Metals & Technologies Corp. Raises Fiscal 2026 Revenue Guidance 62% at Midpoint to $10–$11 Million and Reaffirms $400–$460 Million Fiscal 2027 Outlook
-
Press Release4 days ago
Beyond the Customs Declaration: Gorian Aduanas Takes a Specialist, Bespoke Approach to Customs Clearance and Complex International Imports
-
Press Release1 week ago
Accountsuspension.com Expands Advanced Enterprise Recovery Solutions to Shield Global E-Commerce Sellers and Digital Entrepreneurs from Revenue Collapse
-
Press Release6 days ago
ChannelLetter.com Opens Factory-Direct Wholesale Channel Letters to Sign Shops With No Minimum Order
-
Press Release1 day ago
Exhibit at CES 2027: Showcasing GENCHI, the Immersive Avatar Service Called Crazy by a U.S. Angel Investor
-
Press Release6 days ago
Arthur Murray Dance Studio Continues Longstanding Three-Step Teaching Tradition
-
Press Release6 days ago
The World’s Best Magazine Releases Issue 16 – October 2026 Edition, Excellence in Action